Will the FDA Approve All 3 of These Cancer Drugs in October?

With the global immunotherapy market expected to tip the scales at $35 billion by 2023, Keytruda looks well on its way to nabbing a sizable chunk of this growth. Written off for dead, Merrimack responded with MM-398, a treatment for pancreatic cancer that … http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=DEEC7BFC2A3645F79ED3A0F91F86E7BE&url=http%3a%2f%2fwww.fool.com%2finvesting%2fgeneral%2f2015%2f09%2f24%2fwill-the-fda-approve-all-3-of-these-cancer-drugs-i.aspx&c=tpDE2r9m2OdZlu8NX2lp4kKv2jutS5_89ZDGdDgY-h0&mkt=en-us